

CONTENTS

CONTENTS	i
ABBREVIATIONS AND ACRONYMS	iii
CHAPTER ONE: INTRODUCTION	1
1.1 Structure and functions of endothelium	1
1.2 Endothelial dysfunction	3
1.2.1 Causes and consequences of endothelial dysfunction	3
1.2.2 Mechanism of endothelial dysfunction	4
1.2.3 Prognostic implications of endothelial dysfunction.....	6
1.2.4 Therapeutic target of endothelial dysfunction.....	7
1.3 Statin therapy beyond lipid-lowering effects in cardiovascular disease	8
1.3.1 Improved endothelial dysfunction.....	8
1.3.2 Anti-oxidant effects of statins.....	10
1.3.3 Anti-inflammatory properties.....	11
1.3.4 Stabilization of plaques.....	12
1.3.5 Anti-thrombotic effects.....	12
1.3.6 Pro-apoptotic function.....	13
1.4 Aim of the study	15
CHAPTER TWO: MATERIALS AND METHODS	16
2.1 Materials	16
2.1.1 Laboratory equipments.....	16
2.1.2 Chemicals, reagents, antibodies and kits.....	17
2.2 Methods	21
2.2.1 Experimental animals.....	21
2.2.2 Atorvastatin treatment	21
2.2.3 Lipid measurements	21
2.2.4 Hindlimb perfusion.....	22
2.2.5 Endothelium-dependent, -independent vasodilatation.....	23
2.2.6 Tissue preparation.....	24
2.2.7 NAD(P)H oxidase activity measurement.....	24

2.2.8	Real-time reverse transcription-polymerase chain reaction.....	25
2.2.9	Western blot.....	29
2.2.10	Immunohistochemistry and image analysis	31
2.2.11	Statistical analysis.....	32
CHAPTER THREE: RESULTS.....		33
3.1	Influence of atorvastatin treatment on serum lipid metabolic parameters.....	33
3.2	Effects of atorvastatin treatment on vascular function.....	34
3.2.1	Endothelium-dependent vasodilatation.....	34
3.2.2	Endothelium-independent vasodilatation	34
3.3	Effects of atorvastatin treatment on oxidative stress	37
3.3.1	NAD(P)H oxidase activity.....	37
3.3.2	Expression of eNOS.....	37
3.4	Effects of atorvastatin treatment on inflammation	40
3.5	Effects of atorvastatin treatment on ERK 1/2 MAPK and NF-κB signaling pathway in the non-perfused diabetic skeletal muscles.....	44
CHAPTER FOUR: DISCUSSION.....		47
4.1	Improvement of atorvastatin on endothelial dysfunction independently of lipid-lowering effect.....	47
4.2	Anti-oxidative effect of atorvastatin in diabetic rats.....	49
4.3	Anti-inflammatory effect of atorvastatin in diabetic rats	52
4.4	ERK1/2, and NF-κB signaling pathways implicated in the improvement of endothelial dysfunction by atorvastatin.....	53
CHAPTER FIVE: CONCLUSIONS.....		57
CHAPTER SIX: STUDY LIMITATIONS AND PERSPECTIVES.....		58
CHAPTER SEVEN: SUMMARY.....		59
REFERENCES.....		61
ACKNOWLEDGMENTS.....		76
CURRICULUM VITAE AND PUBLICATIONS.....		77
STATEMENT IN LIEU OF OATH.....		79